Robinson, Jennifer G.

Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry

Nanna, M. G., Navar, A. M., Zakroysky, P., Xiang, Q., Goldberg, A. C., Robinson, J., Roger, V. L., Virani, S. S., Wilson, P. W. F., Elassal, J., et al. (2018) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 122

Effect of Long-Chain ω-3 Fatty Acids and Lutein + Zeaxanthin Supplements on Cardiovascular Outcomes: Results of the Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial

Bonds, D. E., Harrington, M., Worrall, B. B., Bertoni, A. G., Eaton, C. B., Hsia, J., Robinson, J., Clemons, T. E., Fine, L. J., & Chew, E. Y. (2014) · JAMA Internal Medicine

Fatty Acid Research and HealthRetinal Diseases and Treatments

Cited by 118

Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry

Navar, A. M., Wang, T. Y., Li, S., Robinson, J. G., Goldberg, A. C., Virani, S., Roger, V. L., Wilson, P. W. F., Elassal, J., Lee, L. V., et al. (2017) · American Heart Journal

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 94

Low-fat dietary pattern and cardiovascular disease: results from the Women’s Health Initiative randomized controlled trial

Prentice, R. L., Aragaki, A. K., Van Horn, L., Thomson, C. A., Beresford, S. A., Robinson, J., Snetselaar, L., Anderson, G. L., Manson, J. E., Allison, M. A., et al. (2017) · The American Journal of Clinical Nutrition

Nutritional Studies and DietCardiovascular Health and Risk Factors

Cited by 91

Curing atherosclerosis should be the next major cardiovascular prevention goal

Robinson, J. G., & Gidding, S. S. (2014) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 87

Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy

Rossouw, J. E., Cushman, M., Greenland, P., Lloyd-Jones, D. M., Bray, P., Kooperberg, C., Pettinger, M., Robinson, J., Hendrix, S., & Hsia, J. (2008) · Archives of Internal Medicine

Menopause: Health Impacts and TreatmentsLipoproteins and Cardiovascular Health

Cited by 85

Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry

Nanna, M. G., Navar, A. M., Wang, T. Y., Mi, X., Virani, S. S., Louie, M. J., Lee, L. V., Goldberg, A. C., Roger, V. L., Robinson, J., et al. (2018) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthPharmaceutical Practices and Patient Outcomes

Cited by 82

Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council

Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 63

Evaluation of the American Heart Association cardiovascular disease prevention guideline for women

Hsia, J., Rodabough, R. J., Manson, J. E., Liu, S., Freiberg, M. S., Graettinger, W., Rosal, M. C., Cochrane, B., Lloyd-Jones, D., Robinson, J. G., et al. (2010) · Circulation: Cardiovascular Quality and Outcomes

Health Promotion and Cardiovascular PreventionCardiovascular Health and Risk Factors

Cited by 45

A multi-ancestry genome-wide study incorporating gene–smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure

Sung, Y. J., de las Fuentes, L., Winkler, T. W., Chasman, D. I., Bentley, A. R., Kraja, A. T., Ntalla, I., Warren, H. R., Guo, X., Schwander, K., et al. (2019) · Human Molecular Genetics

Genetic Associations and EpidemiologyBlood Pressure and Hypertension Studies

Cited by 43

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years

Farnier, M., Colhoun, H. M., Sasiela, W. J., Edelberg, J. M., Asset, G., & Robinson, J. G. (2017) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthMedication Adherence and Compliance

Cited by 30